The Clorox Company filed its first-quarter fiscal year 2027 earnings release on November 2, 2026, reporting results for the three-month period ended September 30, 2026, with net sales of $1.91 billion and diluted EPS of $1.39.

Key Highlights

  • Net sales increased 33% to $1.91 billion, with the GOJO acquisition contributing about 15 points of that growth.
  • Organic sales increased 18%, reflecting the impact of lapping the ERP transition-related inventory drawdown in the year-ago quarter.
  • Diluted EPS rose 114% to $1.39, compared to $0.65 in the first quarter of fiscal year 2026.
  • Adjusted EPS increased 82% to $1.55, from $0.85 in the year-ago quarter.
  • Gross margin decreased 130 basis points to 40.4% from 41.7%, driven primarily by higher commodity costs and higher manufacturing and logistics costs.
  • Year-to-date net cash provided by operations was $143 million, up 54% from $93 million in the year-ago period.
  • Full-year adjusted EPS guidance of $5.70 to $6.00 was maintained, though the company expects results closer to the low end of the range.

Clorox Reports First-Quarter Fiscal 2027 Results Amid GOJO Integration and Cost Pressures

The Clorox Company (NYSE:CLX) reported first-quarter fiscal year 2027 results on November 2, 2026, covering the period ended September 30, 2026. According to the filing, net sales grew 33% to $1.91 billion, with approximately 15 points of that increase attributable to the GOJO acquisition. Organic sales growth of 18% was described as primarily reflecting the benefit of lapping the ERP transition-related inventory drawdown that weighed on the year-ago quarter. The company noted that the ERP-related drawdown reduced fiscal year 2026 earnings per share by about 90 cents and reduced fiscal year 2026 adjusted EPS growth by about 23%.

Gross margin contracted 130 basis points to 40.4%, the filing disclosed, driven by higher commodity costs and higher manufacturing and logistics costs, partially offset by higher volume and cost savings. The GOJO inventory step-up accounted for about 50 basis points of that contraction. Diluted EPS of $1.39 represented a 114% increase from $0.65 in the prior-year quarter, while adjusted EPS of $1.55 was up 82% from $0.85. Adjusted EPS and organic sales growth are non-GAAP measures, the company noted, with reconciliations provided in the filing.

Across segments, Health and Wellness net sales increased 62%, with the GOJO acquisition contributing approximately 39 points. Household net sales rose 17%, Lifestyle net sales rose 16%, and International net sales increased 11%, with organic sales up 9% in that segment. For the full fiscal year 2027, the company said it is maintaining its net sales outlook of up 13% to 14% and its adjusted EPS range of $5.70 to $6.00, but now expects adjusted EPS results closer to the low end of the range, citing higher-than-normal inflationary headwinds. Gross margin is now expected to be about 41.5%, revised from prior guidance, and selling and administrative expenses are now expected to be about 15.5% of net sales.

What Was Disclosed

Clorox disclosed first-quarter fiscal 2027 financial results, including net sales of $1.91 billion, diluted EPS of $1.39, and adjusted EPS of $1.55, alongside updated full-year fiscal 2027 gross margin and selling and administrative expense guidance, while maintaining its sales and adjusted EPS outlook ranges.